Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3- heteroaryl ureas with improved in vitro pharmacokinetic properties

E. Jeffrey North, Michael S. Scherman, David F. Bruhn, Jerrod S. Scarborough, Marcus M. Maddox, Victoria Jones, Anna Grzegorzewicz, Lei Yang, Tamara Hess, Christophe Morisseau, Mary Jackson, Michael R. McNeil, Richard E. Lee

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Out of the prominent global ailments, tuberculosis (TB) is still one of the leading causes of death worldwide due to infectious disease. Development of new drugs that shorten the current tuberculosis treatment time and have activity against drug resistant strains is of utmost importance. Towards these goals we have focused our efforts on developing novel anti-TB compounds with the general structure of 1-adamantyl-3-phenyl urea. This series is active against Mycobacteria and previous lead compounds were found to inhibit the membrane transporter MmpL3, the protein responsible for mycolic acid transport across the plasma membrane. However, these compounds suffered from poor in vitro pharmacokinetic (PK) profiles and they have a similar structure/SAR to inhibitors of human soluble epoxide hydrolase (sEH) enzymes. Therefore, in this study the further optimization of this compound class was driven by three factors: (1) to increase selectivity for anti-TB activity over human sEH activity, (2) to optimize PK profiles including solubility and (3) to maintain target inhibition. A new series of 1-adamantyl-3-heteroaryl ureas was designed and synthesized replacing the phenyl substituent of the original series with pyridines, pyrimidines, triazines, oxazoles, isoxazoles, oxadiazoles and pyrazoles. This study produced lead isoxazole, oxadiazole and pyrazole substituted adamantyl ureas with improved in vitro PK profiles, increased selectivity and good anti-TB potencies with sub μg/mL minimum inhibitory concentrations.

Original languageEnglish
Pages (from-to)2587-2599
Number of pages13
JournalBioorganic and Medicinal Chemistry
Volume21
Issue number9
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Pharmacokinetics
Oxadiazoles
Isoxazoles
Urea
Epoxide Hydrolases
Tuberculosis
Oxazoles
Pyrazoles
Mycolic Acids
Pyridines
Lead compounds
Pyrimidines
Triazines
Membrane Transport Proteins
Cell membranes
Pharmaceutical Preparations
Solubility
Microbial Sensitivity Tests
Mycobacterium
Human Activities

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3- heteroaryl ureas with improved in vitro pharmacokinetic properties. / North, E. Jeffrey; Scherman, Michael S.; Bruhn, David F.; Scarborough, Jerrod S.; Maddox, Marcus M.; Jones, Victoria; Grzegorzewicz, Anna; Yang, Lei; Hess, Tamara; Morisseau, Christophe; Jackson, Mary; McNeil, Michael R.; Lee, Richard E.

In: Bioorganic and Medicinal Chemistry, Vol. 21, No. 9, 01.05.2013, p. 2587-2599.

Research output: Contribution to journalArticle

North, EJ, Scherman, MS, Bruhn, DF, Scarborough, JS, Maddox, MM, Jones, V, Grzegorzewicz, A, Yang, L, Hess, T, Morisseau, C, Jackson, M, McNeil, MR & Lee, RE 2013, 'Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3- heteroaryl ureas with improved in vitro pharmacokinetic properties', Bioorganic and Medicinal Chemistry, vol. 21, no. 9, pp. 2587-2599. https://doi.org/10.1016/j.bmc.2013.02.028
North, E. Jeffrey ; Scherman, Michael S. ; Bruhn, David F. ; Scarborough, Jerrod S. ; Maddox, Marcus M. ; Jones, Victoria ; Grzegorzewicz, Anna ; Yang, Lei ; Hess, Tamara ; Morisseau, Christophe ; Jackson, Mary ; McNeil, Michael R. ; Lee, Richard E. / Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3- heteroaryl ureas with improved in vitro pharmacokinetic properties. In: Bioorganic and Medicinal Chemistry. 2013 ; Vol. 21, No. 9. pp. 2587-2599.
@article{c5ce3824d6714c0bb09e09994d381a3b,
title = "Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3- heteroaryl ureas with improved in vitro pharmacokinetic properties",
abstract = "Out of the prominent global ailments, tuberculosis (TB) is still one of the leading causes of death worldwide due to infectious disease. Development of new drugs that shorten the current tuberculosis treatment time and have activity against drug resistant strains is of utmost importance. Towards these goals we have focused our efforts on developing novel anti-TB compounds with the general structure of 1-adamantyl-3-phenyl urea. This series is active against Mycobacteria and previous lead compounds were found to inhibit the membrane transporter MmpL3, the protein responsible for mycolic acid transport across the plasma membrane. However, these compounds suffered from poor in vitro pharmacokinetic (PK) profiles and they have a similar structure/SAR to inhibitors of human soluble epoxide hydrolase (sEH) enzymes. Therefore, in this study the further optimization of this compound class was driven by three factors: (1) to increase selectivity for anti-TB activity over human sEH activity, (2) to optimize PK profiles including solubility and (3) to maintain target inhibition. A new series of 1-adamantyl-3-heteroaryl ureas was designed and synthesized replacing the phenyl substituent of the original series with pyridines, pyrimidines, triazines, oxazoles, isoxazoles, oxadiazoles and pyrazoles. This study produced lead isoxazole, oxadiazole and pyrazole substituted adamantyl ureas with improved in vitro PK profiles, increased selectivity and good anti-TB potencies with sub μg/mL minimum inhibitory concentrations.",
author = "North, {E. Jeffrey} and Scherman, {Michael S.} and Bruhn, {David F.} and Scarborough, {Jerrod S.} and Maddox, {Marcus M.} and Victoria Jones and Anna Grzegorzewicz and Lei Yang and Tamara Hess and Christophe Morisseau and Mary Jackson and McNeil, {Michael R.} and Lee, {Richard E.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.bmc.2013.02.028",
language = "English",
volume = "21",
pages = "2587--2599",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3- heteroaryl ureas with improved in vitro pharmacokinetic properties

AU - North, E. Jeffrey

AU - Scherman, Michael S.

AU - Bruhn, David F.

AU - Scarborough, Jerrod S.

AU - Maddox, Marcus M.

AU - Jones, Victoria

AU - Grzegorzewicz, Anna

AU - Yang, Lei

AU - Hess, Tamara

AU - Morisseau, Christophe

AU - Jackson, Mary

AU - McNeil, Michael R.

AU - Lee, Richard E.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Out of the prominent global ailments, tuberculosis (TB) is still one of the leading causes of death worldwide due to infectious disease. Development of new drugs that shorten the current tuberculosis treatment time and have activity against drug resistant strains is of utmost importance. Towards these goals we have focused our efforts on developing novel anti-TB compounds with the general structure of 1-adamantyl-3-phenyl urea. This series is active against Mycobacteria and previous lead compounds were found to inhibit the membrane transporter MmpL3, the protein responsible for mycolic acid transport across the plasma membrane. However, these compounds suffered from poor in vitro pharmacokinetic (PK) profiles and they have a similar structure/SAR to inhibitors of human soluble epoxide hydrolase (sEH) enzymes. Therefore, in this study the further optimization of this compound class was driven by three factors: (1) to increase selectivity for anti-TB activity over human sEH activity, (2) to optimize PK profiles including solubility and (3) to maintain target inhibition. A new series of 1-adamantyl-3-heteroaryl ureas was designed and synthesized replacing the phenyl substituent of the original series with pyridines, pyrimidines, triazines, oxazoles, isoxazoles, oxadiazoles and pyrazoles. This study produced lead isoxazole, oxadiazole and pyrazole substituted adamantyl ureas with improved in vitro PK profiles, increased selectivity and good anti-TB potencies with sub μg/mL minimum inhibitory concentrations.

AB - Out of the prominent global ailments, tuberculosis (TB) is still one of the leading causes of death worldwide due to infectious disease. Development of new drugs that shorten the current tuberculosis treatment time and have activity against drug resistant strains is of utmost importance. Towards these goals we have focused our efforts on developing novel anti-TB compounds with the general structure of 1-adamantyl-3-phenyl urea. This series is active against Mycobacteria and previous lead compounds were found to inhibit the membrane transporter MmpL3, the protein responsible for mycolic acid transport across the plasma membrane. However, these compounds suffered from poor in vitro pharmacokinetic (PK) profiles and they have a similar structure/SAR to inhibitors of human soluble epoxide hydrolase (sEH) enzymes. Therefore, in this study the further optimization of this compound class was driven by three factors: (1) to increase selectivity for anti-TB activity over human sEH activity, (2) to optimize PK profiles including solubility and (3) to maintain target inhibition. A new series of 1-adamantyl-3-heteroaryl ureas was designed and synthesized replacing the phenyl substituent of the original series with pyridines, pyrimidines, triazines, oxazoles, isoxazoles, oxadiazoles and pyrazoles. This study produced lead isoxazole, oxadiazole and pyrazole substituted adamantyl ureas with improved in vitro PK profiles, increased selectivity and good anti-TB potencies with sub μg/mL minimum inhibitory concentrations.

UR - http://www.scopus.com/inward/record.url?scp=84876129597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876129597&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2013.02.028

DO - 10.1016/j.bmc.2013.02.028

M3 - Article

VL - 21

SP - 2587

EP - 2599

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 9

ER -